KT6 971
Alternative Names: KT6-971; S-556971Latest Information Update: 05 Nov 2023
At a glance
- Originator Kotobuki Pharmaceutical
- Class Antihyperlipidaemics
- Mechanism of Action Cholesterol absorption inhibitors; NPC1L1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dyslipidaemias
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Dyslipidaemias in Europe (PO)
- 21 Aug 2015 Phase-II development is ongoing in Japan
- 21 Aug 2015 KT6 971 is no longer licensed to Shionogi in World